Natural Products Drug Discovery and Their Pharmacological Applications

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Natural Products".

Deadline for manuscript submissions: 31 August 2026 | Viewed by 806

Special Issue Editor


E-Mail Website
Guest Editor
Departamento de Farmacología, IFEC—Instituto de Farmacología Experimental de Córdoba (CONICET-UNC), Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina
Interests: essential oils; chronic inflammatory diseases; lipid metabolism
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Natural-product-derived compounds obtained from plants, animals, and microorganisms are characterized by remarkable structural diversity and a wide spectrum of biological activities, often associated with favorable safety and efficacy profiles. These features have established natural products as a key component of drug discovery, and they continue to represent a rich and largely unexplored source of bioactive molecules with significant therapeutic potential. In the context of an aging global population, neurodegenerative diseases are expected to become increasingly prevalent, underscoring the urgent need for preventive and disease-modifying therapeutic strategies.

This Special Issue will primarily focus on plant-derived natural products as promising candidates for the prevention and treatment of neurodegenerative disorders, given their pleiotropic mechanisms of action and their suitability for addressing the complex and multifactorial nature of these diseases. We welcome original research articles and reviews that address recent advances in natural-product-based drug discovery. Contributions may include in vitro and in vivo experimental studies, novel extraction and screening approaches, structure–activity relationship analyses, investigations of molecular mechanisms of action, pharmacokinetic and pharmacodynamic evaluations, and innovative drug delivery systems designed to improve stability, bioavailability, and therapeutic efficacy. Particular emphasis will be placed on translational research bridging basic studies, preclinical models, and clinical relevance. While the main focus will be on plant-derived compounds and neurodegeneration, contributions involving natural products from other sources or targeting additional pathological conditions are also encouraged, provided that they offer clear pharmacological or pharmaceutical relevance.

The Special Issue of Pharmaceutics invites submissions related to drug delivery systems and drug design, while the Special Issue Pharmaceuticals encourages contributions centered on clinical or pathological aspects.

You may choose our Joint Special Issue in Pharmaceutics.

Dr. Rosana Crespo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • natural product
  • pharmaceutical applications
  • neurodegenerative disorders

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 3221 KB  
Article
A Standard Herbal Formula, CGAC, Attenuates Bone Loss by Normalizing Low-Bone Turnover Stagnation in an Orchiectomy-Induced Mouse Model
by Dong-Cheol Baek, Min-Young Chae, Tae-Wook Woo, Chang-Gue Son and Eun-Jung Lee
Pharmaceuticals 2026, 19(4), 555; https://doi.org/10.3390/ph19040555 - 31 Mar 2026
Viewed by 449
Abstract
Background/Objectives: Osteoporosis is a progressive systemic skeletal disease, with male osteoporosis emerging as a critical global concern due to high morbidity and mortality from fractures. This study investigated the anti-osteoporotic potential of CGAC—a herbal mixture of Cervus elaphus Linnaeus, Glycine max [...] Read more.
Background/Objectives: Osteoporosis is a progressive systemic skeletal disease, with male osteoporosis emerging as a critical global concern due to high morbidity and mortality from fractures. This study investigated the anti-osteoporotic potential of CGAC—a herbal mixture of Cervus elaphus Linnaeus, Glycine max (L.) Merr., Angelica gigas Nakai, and Cnidium officinale Makino—and its underlying mechanisms in an orchiectomized (ORX) mouse model. Methods: C57BL/6J mice underwent ORX for 8 weeks, followed by CGAC administration (250 and 500 mg/kg) for an additional 8 weeks. Molecular mechanisms were further validated using MG63 osteoblastic and RAW 264.7 osteoclast assays. Results: ORX induced severe osteoporotic phenotypes, including significant reductions in bone mineral density (BMD) and trabecular microarchitecture. Notably, at the time point examined, ORX was associated with a suppressed bone remodeling state, reflected by reductions in both TRAP-positive osteoclasts and ALP-positive osteoblasts, together with lower serum BALP, CTX-1, and Gla/Glu-OC ratio. Conversely, CGAC normalized this stagnant state and restored physiological remodeling. This was accompanied by reduced marrow fat accumulation through the AMPK signaling axis, which upregulated Runx2 and downregulated PPAR-γ. In vitro results confirmed that CGAC promoted osteoblast differentiation and mineralization while suppressing RANKL-induced osteoclastogenesis. These actions suggest that CGAC may be involved in regulating Wnt/β-catenin signaling. Conclusions: Overall, CGAC is a promising therapeutic candidate for male osteoporosis, offering pharmacological benefits particularly relevant to aging populations. Full article
Show Figures

Figure 1

Back to TopTop